{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:23:37Z","timestamp":1773714217021,"version":"3.50.1"},"reference-count":35,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","award":["Seoul National University Hospital"],"award-info":[{"award-number":["Seoul National University Hospital"]}],"id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research Foundation (NRF)","award":["2015M3A9B6074045"],"award-info":[{"award-number":["2015M3A9B6074045"]}]},{"name":"Support Program for Women in Science, Engineering and Technology  through NRF","award":["2019H1C3A 10322224"],"award-info":[{"award-number":["2019H1C3A 10322224"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Adalimumab is used at 40-mg dose to treat systemic inflammatory diseases. Given the impact of adverse drug reactions (ADRs), which particularly result in the discontinuation of adalimumab therapy in female patients, this study examined whether sex affects the frequency and type of ADRs induced by adalimumab. In this study, the prescription records and laboratory data of patients aged \u226519 years who had been admitted to the Seoul National University Hospital (SNUH) and prescribed adalimumab were analyzed using an electronic medical record database. The analysis revealed that female patients more frequently experienced adalimumab-induced ADRs compared with male patients (63.2% vs. 52.2%). The incidence of ADRs was significantly higher in female patients with ankylosing spondylitis or rheumatoid arthritis than in male patients with similar conditions (81.5% vs. 60.7% or 64.4% vs. 50.0%, respectively). The median body weight (BW) was lower in female patients than in male patients (54.0 vs. 66.0 kg). Moreover, the incidence of ADRs in patients with a BW of &lt;54.0 kg (i.e., the median female BW) was higher than for those with a BW of \u226554.0 kg, in both males and females. Our results suggested that the predominance of ADRs induced by adalimumab in females was because of their relatively lower BW. This suggests the importance of BW as a determining factor in sex disparity of ADR occurrences.<\/jats:p>","DOI":"10.3390\/jcm9020461","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T11:50:28Z","timestamp":1581076228000},"page":"461","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Body Weight as a Determining Factor in the Predominance of Adverse Drug Reactions Induced by Fixed-Dose Adalimumab Injections in Female Patients in a Korean Hospital Setting"],"prefix":"10.3390","volume":"9","author":[{"given":"Kwi Suk","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-6436","authenticated-orcid":false,"given":"Young Hee","family":"Choi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dongguk University Seoul, Goyang-si, Gyeonggi-do 10326, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aree","family":"Moon","sequence":"additional","affiliation":[{"name":"Duksung Innovative Drug Center, College of Pharmacy, Duksung Women\u2019s University, Seoul 01369, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Geon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Korea"},{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors-state of knowledge","volume":"10","author":"Lis","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"ref_2","first-page":"763","article-title":"Adalimumab for the treatment of Crohn\u2019s disease","volume":"2","author":"Cassinotti","year":"2008","journal-title":"Biologics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12325-019-01145-8","article-title":"Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: An updated analysis","volume":"37","author":"Burmester","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_4","unstructured":"FDA (2019, July 25). Approval Package for BLA125057\/S280\/, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfdadocs\/bla\/2010\/125057Orig1s0213.pdf."},{"key":"ref_5","first-page":"643","article-title":"Serious neutropenia following etanercept administration in a 62 years female patient of rheumatoid arthritis","volume":"58","author":"Datta","year":"2010","journal-title":"J. Assoc. Physicians India"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2217\/ijr.13.6","article-title":"Adalimumab: 8 years of experience in rheumatoid arthritis","volume":"8","author":"Tayar","year":"2013","journal-title":"Int. J. Clin. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/acr.21798","article-title":"Racial\/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients","volume":"65","author":"Chu","year":"2013","journal-title":"Arthritis Care Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MIB.0000000000000981","article-title":"Sex is associated with adalimumab side effects and drug survival in patients with Crohn\u2019s disease","volume":"23","author":"Lie","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/ibd.21888","article-title":"Systematic assessment of factors influencing preferences of Crohn\u2019s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF Trial)","volume":"18","author":"Vavricka","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalization and surgery towards anti-TNF\u03b1 therapy results from the COIN study","volume":"63","author":"Mangen","year":"2014","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/apt.14318","article-title":"Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalized pharmacokinetics in patients with Crohn\u2019s disease: A sub-analysis of the DIAMOND trial","volume":"46","author":"Nakase","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/cp.1999.v66.103400001","article-title":"Gender related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"66","author":"Luzier","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","first-page":"3","article-title":"Sex and gender differences in clinical medicine","volume":"Volume 214","author":"Seeland","year":"2012","journal-title":"Sex and Gender Differences in Pharmacology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/978-3-642-30726-3_19","article-title":"Sex differences in the drug therapy for oncologic diseases","volume":"Volume 214","author":"Schmetzer","year":"2012","journal-title":"Sex and Gender Differences in Pharmacology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00404-017-4363-3","article-title":"Gender based personalized pharmacotherapy: A systemic review","volume":"295","author":"Islam","year":"2017","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"49","author":"Soldin","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(08)00001-9","article-title":"Gender differences in pharmacological response","volume":"83","author":"Amderson","year":"2008","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1155\/2011\/724813","article-title":"Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn\u2019s disease: Results of the adalimumab in Canadian subjects with moderate to severe Crohn\u2019s disease (ACCESS) trial","volume":"25","author":"Panaccione","year":"2011","journal-title":"Can. J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/bja\/aet127","article-title":"Sex differences in pain: A brief review of clinical and experimental finding","volume":"111","author":"Bartley","year":"2013","journal-title":"Br. J. Anaesth."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.crohns.2014.01.012","article-title":"Adalimumab for Crohn\u2019s disease: Long-term sustained benefit in a population-based cohort of 438 patients","volume":"8","author":"Peters","year":"2014","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_21","unstructured":"National Institute for Health and Care Excellence (2019, July 25). Infliximab and Adalimumab for Crohn\u2019s Disease. Technology Appraisal Guidance. Available online: https:\/\/www.nice.org.uk\/guidance\/TA187."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/14397595.2014.958274","article-title":"Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012","volume":"25","author":"Sato","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/14712598.2019.1564033","article-title":"Biosimilars of adalimumab: The upcoming challenge in IBD","volume":"19","author":"Fiorino","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_24","first-page":"289","article-title":"The economic impact of the introduction of biosimilars in inflammatory bowel disease","volume":"11","author":"Severs","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lesuis, N., Befrits, R., Nyberg, F., and van Vollenhoven, R.F. (2012). Gender and the treatment of immune mediated chronic inflammatory diseases: Rheumatoid arthritis, inflammatory bowel disease and psoriasis: An observational study. BMC Med., 10.","DOI":"10.1186\/1741-7015-10-82"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16068","DOI":"10.1038\/s41598-018-34293-y","article-title":"Drug survival of biologics in treating psoriasis: A meta-analysis of real-world evidence","volume":"8","author":"Lin","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11926-018-0744-2","article-title":"Gender differences in axial spondyloarthritis: Women are not so lucky","volume":"20","author":"Rusman","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.3748\/wjg.v18.i47.6967","article-title":"Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease","volume":"18","author":"Zelinkova","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/ecco-jcc\/jjy050","article-title":"Clinical benefit of long-term adalimumab treatment in patients with Crohn\u2019s disease following loss of response or intolerance to infliximab: 96-week efficacy data from GAIN\/ADHERE Trials","volume":"12","author":"Panaccione","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2340\/00015555-2571","article-title":"Adalimumab dose tapering in psoriasis: Predictive factors for maintenance of complete clearance","volume":"97","author":"Hansel","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14740338.4.4.637","article-title":"Adalimumab: A review of side effect","volume":"4","author":"Scheinfeld","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/14397595.2017.1304159","article-title":"Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients","volume":"28","author":"Harigai","year":"2008","journal-title":"Mod. Rheumatol."},{"key":"ref_33","unstructured":"Chao, Y.S., and Visintini, S. (2019, July 25). Biologics Dose Escalation for the Treatment of Inflammatory Bowel Disease: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines. Available online: http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0."},{"key":"ref_34","unstructured":"(2013). Humira (Adalimumab) Package Insert, AbbVie Inc.. Available online: https:\/\/www.humira.com."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: Results from the DANBIO and ICEBIO registries","volume":"55","author":"Hojgaard","year":"2016","journal-title":"Rheumatology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/2\/461\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:55:44Z","timestamp":1760172944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/2\/461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["jcm9020461"],"URL":"https:\/\/doi.org\/10.3390\/jcm9020461","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]}}}